Published in Biometrics on December 01, 2010
Surrogate measures and consistent surrogates. Biometrics (2013) 3.59
Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis (2014) 2.46
Principal stratification--uses and limitations. Int J Biostat (2011) 1.59
Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide. AIDS Res Hum Retroviruses (2011) 1.52
A threshold method for immunological correlates of protection. BMC Med Res Methodol (2013) 1.41
Comparing biomarkers as principal surrogate endpoints. Biometrics (2011) 1.39
A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpoint. Biometrics (2012) 1.11
Design and estimation for evaluating principal surrogate markers in vaccine trials. Biometrics (2013) 1.08
A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. Stat Commun Infect Dis (2011) 1.06
Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy. Biostatistics (2013) 1.01
Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials. Biostatistics (2011) 0.89
Bayesian inference for the causal effect of mediation. Biometrics (2012) 0.86
Comparing and combining biomarkers as principle surrogates for time-to-event clinical endpoints. Stat Med (2014) 0.83
Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition. J Causal Inference (2015) 0.79
Augmented trial designs for evaluation of principal surrogates. Biostatistics (2016) 0.75
Hard, harder, hardest: principal stratification, statistical identifiability, and the inherent difficulty of finding surrogate endpoints. Emerg Themes Epidemiol (2014) 0.75
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Principal stratification in causal inference. Biometrics (2002) 12.34
Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med (1989) 11.07
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis (2005) 5.14
The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics (2000) 4.05
Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics (1998) 3.72
Toward Causal Inference With Interference. J Am Stat Assoc (2008) 2.85
Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med (2006) 2.79
Augmented designs to assess immune response in vaccine trials. Biometrics (2006) 2.78
Evaluating candidate principal surrogate endpoints. Biometrics (2008) 2.74
Evaluating a surrogate endpoint at three levels, with application to vaccine development. Stat Med (2008) 2.50
Related causal frameworks for surrogate outcomes. Biometrics (2009) 2.46
On meta-analytic assessment of surrogate outcomes. Biostatistics (2000) 2.41
T cell development and receptor diversity during aging. Curr Opin Immunol (2005) 2.29
Stability of natural self-reactive antibody repertoires during aging. J Clin Immunol (1999) 0.95
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr (2003) 7.23
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis (2012) 3.42
Bacterial coaggregation: an integral process in the development of multi-species biofilms. Trends Microbiol (2003) 3.17
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis (2012) 2.68
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One (2013) 1.94
Mucosa-associated bacterial diversity in relation to human terminal ileum and colonic biopsy samples. Appl Environ Microbiol (2007) 1.84
Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide. AIDS Res Hum Retroviruses (2011) 1.52
Microbial characterization of biofilms in domestic drains and the establishment of stable biofilm microcosms. Appl Environ Microbiol (2003) 1.47
Molecular analysis of the subgingival microbiota in health and disease. Appl Environ Microbiol (2006) 1.45
Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop. Clin Trials (2012) 1.43
Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS (2004) 1.41
Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. J Immunol Methods (2011) 1.40
HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission. PLoS One (2010) 1.36
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol (2013) 1.26
HIV-1 vaccines and adaptive trial designs. Sci Transl Med (2011) 1.21
Effects of a chlorhexidine gluconate-containing mouthwash on the vitality and antimicrobial susceptibility of in vitro oral bacterial ecosystems. Appl Environ Microbiol (2003) 1.19
Shear rate moderates community diversity in freshwater biofilms. Appl Environ Microbiol (2004) 1.16
Intrapatient diversity and its correlation with viral setpoint in human immunodeficiency virus type 1 CRF02_A/G-IbNG infection. J Virol (2002) 1.14
Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials. Biometrics (2008) 1.03
MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load. PLoS One (2012) 1.03
Exposure of sink drain microcosms to triclosan: population dynamics and antimicrobial susceptibility. Appl Environ Microbiol (2003) 1.01
Effects of quaternary-ammonium-based formulations on bacterial community dynamics and antimicrobial susceptibility. Appl Environ Microbiol (2004) 0.99
Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission. J Clin Invest (2015) 0.98
Comparative prediction of perinatal human immunodeficiency virus type 1 transmission, using multiple virus load markers. J Infect Dis (2003) 0.95
Selection for high-level resistance by chronic triclosan exposure is not universal. J Antimicrob Chemother (2004) 0.94
AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection. Vaccine (2008) 0.93
nCal: an R package for non-linear calibration. Bioinformatics (2013) 0.92
Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines. Vaccine (2004) 0.91
Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection. Hum Vaccin Immunother (2015) 0.91
In vitro study of the effect of cationic biocides on bacterial population dynamics and susceptibility. Appl Environ Microbiol (2008) 0.91
HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. PLoS Pathog (2013) 0.90
In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities. AIDS Res Hum Retroviruses (2013) 0.87
Cross-sectional study of factors that influence the 25-hydroxyvitamin D status in pregnant women and in cord blood in Germany. Br J Nutr (2013) 0.85
Effects of triclosan-containing rinse on the dynamics and antimicrobial susceptibility of in vitro plaque ecosystems. Antimicrob Agents Chemother (2003) 0.85
In-utero transmission of quasispecies among human immunodeficiency virus type 1 genotypes. Virology (2003) 0.84
Biocide abuse and antimicrobial resistance: being clear about the issues. J Antimicrob Chemother (2002) 0.81
Influence of gentamicin and tobramycin on binary biofilm formation by co-cultures of Burkholderia cepacia and Pseudomonas aeruginosa. J Basic Microbiol (2005) 0.81
Biofilms, homoserine lactones and biocide susceptibility. J Antimicrob Chemother (2004) 0.80
Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop. J Acquir Immune Defic Syndr (2007) 0.79
A Bayesian Framework for Estimating Vaccine Efficacy per Infectious Contact. Ann Appl Stat (2008) 0.79
Synthesis and bioluminescence-inducing properties of autoinducer (S)-4,5-dihydroxypentane-2,3-dione and its enantiomer. Bioorg Med Chem Lett (2010) 0.78
Reply to Richie and Villasante. J Infect Dis (2012) 0.77
Calibration weighted estimation of semiparametric transformation models for two-phase sampling. Stat Med (2015) 0.75
Testing and estimation of time-varying cause-specific hazard ratios with covariate adjustment. Biometrics (2008) 0.75
Antinociceptive effects of epidural administration of hydromorphone in conscious cats. Am J Vet Res (2009) 0.75
Plasma concentrations of buprenorphine after epidural administration in conscious cats. Res Vet Sci (2010) 0.75
Humane care includes respect for patients' religious beliefs. Nurs Stand (2009) 0.75
Creating an integrated clinical enterprise at the University of Kentucky: the emergence of UK HealthCare. Acad Med (2007) 0.75